Erythropoietin conjugates

US6340742B1 · kind B1 · utility

Assignee

• Roche Diagnostics GMBH · DE

Inventors

• Josef Burg · Weilheim, DE
• Bernd Hilger · Indianapolis, US
• Hans-Peter Josel · Weilheim, DE

Key dates

• Filing date: Jun 28, 2000
• Grant date: Jan 22, 2002
• Expiry date: Jun 28, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Erythropoietin glycoprotein products are disclosed which have the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity in vivo. In addition, compared with conventional PEG-EPO conjugates, the conjugates of this invention have superior clinical properties. The present invention also includes a method for the treatment of anemia in a human employing the novel erythropoietin glycoprotein products as well as a method for preparing the erythropoietin glycoprotein products.